-
| Exchange | NYSE |
|---|---|
| CurrencyCode | USD |
| ISIN | US30054Y1073 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | None |
|---|---|
| PE Ratio | nan |
| Target Price | nan |
| Dividend Yield | nan% |
| Beta | nan |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for EVMN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026